Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance.
Praxis is seeking an experienced leader to serve as the strategic and operational owner of ulixacaltamide within our Movement Disorders franchise. This individual will define the brand strategy, lead launch planning and execution, and partner cross-functionally to ensure organizational readiness and commercial success.
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance.
Praxis Precision Medicines, Inc.